Interested in Investment Opportunities?
Contact UsOther content in this Stream
Liminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)
The FDA confirmed that the resubmission is a complete, Class 2 response and has provided a Prescription Drug User Fee Act ("PDUFA") target action date of March 5, 2021.
Liminal Biosciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference
LMNL announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at The H.C. Wainwright 22nd Annual Global Investment Conference
Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)
Liminal, through its U.S. subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the Biologics License Application (BLA) for Ryplazim® (plasminogen) (Ryplazim®) with the U.S. FDA
